Literature DB >> 29436221

Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.

Alexandra N Tsoras1, Julie A Champion1.   

Abstract

Peptide subunit vaccines are desirable because they increase control over the immune response and safety of the vaccine by reducing the risk of off-target responses to molecules other than the target antigen. The immunogenicity of most peptides, however, is low. Peptide nanoclusters (PNC) are proposed as a subunit peptide vaccine delivery system made completely of cross-linked peptide antigen that could improve the immunogenicity of a peptide vaccine. Proof of concept is demonstrated with oncofetal antigen (OFA), an immature laminin receptor protein expressed by many hematologic cancer cells but not by healthy cells. Peptide epitopes from this protein, called OFA 1, 2, and 3, were synthesized into PNC as a potential cancer peptide vaccine delivery system. PNC were formed by desolvation and stabilized with disulfide bonds using a trithiol cross-linker. Cysteines were added to the C-terminus of each peptide to assist in this cross-linking step, denoted OFA 1C, 2C, and 3C PNC. OFA 2C was found to form the smallest PNC, 148 ± 15 nm in diameter and stable in solution. This size is in the range where particles are readily internalized by dendritic cells (DCs) and may also passively diffuse to regional lymph nodes. OFA 2C PNC and soluble OFA 2C were internalized similarly by DCs in vitro, but only PNC resulted in significant peptide presentation by DCs. This indicates the potential for PNC to improve immune activation against this antigen. Additionally, PNC displayed higher retention at the intradermal injection site in vivo than soluble peptide, allowing more time to interact with DCs in an area of increased DC activity. While offering traditional nanoparticle benefits such as increased DC recognition, slower diffusion, and potential for multivalent cellular interactions, PNC also maximize antigen delivered per particle while minimizing off-target material delivery because the antigens are the main building blocks of the particle. With these properties, PNC are a delivery system with potential to increase peptide subunit vaccine immunogenicity for OFA and other peptide antigens.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29436221     DOI: 10.1021/acs.bioconjchem.8b00079

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

3.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

4.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

Review 5.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

6.  Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

Authors:  Masoud Delfi; Rossella Sartorius; Milad Ashrafizadeh; Esmaeel Sharifi; Yapei Zhang; Piergiuseppe De Berardinis; Ali Zarrabi; Rajender S Varma; Franklin R Tay; Bryan Ronain Smith; Pooyan Makvandi
Journal:  Nano Today       Date:  2021-03-11       Impact factor: 18.962

7.  Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses.

Authors:  Alexandra N Tsoras; Kong M Wong; Anant K Paravastu; Julie A Champion
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.